Related Experiment Video
Updated: Oct 21, 2025

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
Down-regulated MicroRNAs in Gastric Carcinoma May Be Targets for Therapeutic Intervention and Replacement Therapy
Ulrich H Weidle1, Fabian Birzele2, Simon Auslaender1
1Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Abstract:
Gastric cancer is one of the leading types of cancer with an annual death toll of 700,000 worldwide. Despite the fact that several agents are approved for its treatment, high percentage of recurrence and intractability of metastatic disease remain a major problem. The identification of new targets and modalities for treatment are therefore of high priority. We have searched the literature for microRNAs down-regulated in gastric cancer with efficacy in gastric cancer-related murine xenograft models after reconstitution therapy. Among the identified miRs were 25 miRs targeting transcription factors, seven of them regulating cell-cycle and apotosis-related targets, and five of them regulating GTPase-related targets such as GAPs and GEFs. According to criteria such as prognostic impact, functional data, and tractability, miR-133 b/a (MCL1) and miR-518 (MDM2) are suggested as potentially valuable targets for further evaluation and possible treatment of gastric cancer.
Insights
Gastric cancer remains a significant global health challenge. This study identifies specific microRNAs, including miR-133b/a and miR-518, as promising therapeutic targets for treating this intractable disease.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastric cancer is a leading cause of cancer death globally, with high recurrence and metastatic disease rates.
- Current treatments face challenges due to disease intractability and recurrence.
- Novel therapeutic targets and treatment modalities are urgently needed for gastric cancer.
Purpose of the Study:
- To identify microRNAs (miRNAs) that are downregulated in gastric cancer and demonstrate efficacy in preclinical models.
- To evaluate the potential of these miRNAs as therapeutic targets for gastric cancer treatment.
Main Methods:
- Literature search for downregulated miRNAs in gastric cancer with demonstrated efficacy in xenograft models.
- Analysis of miRNA targets, focusing on transcription factors, cell cycle, apoptosis, and GTPase-related pathways.
- Evaluation of miRNAs based on prognostic impact, functional data, and tractability.
Main Results:
- Identified 25 miRNAs targeting transcription factors, including seven regulating cell-cycle and apoptosis, and five regulating GTPase-related targets.
- miR-133b/a (targeting MCL1) and miR-518 (targeting MDM2) were among the identified miRNAs.
- These specific miRNAs showed potential based on prognostic impact and functional data.
Conclusions:
- miR-133b/a and miR-518 are suggested as potentially valuable targets for further investigation in gastric cancer.
- Reconstitution therapy with specific miRNAs may offer a novel treatment strategy for gastric cancer.
- Further evaluation is warranted to explore the therapeutic potential of these miRNAs in gastric cancer treatment.
Related Concept Videos
MicroRNAs
Experimental RNAi
Abnormal Proliferation

